Julie Rowe1, Sukeshi Patel2, Marcela Mazo-Canola3, Alberto Parra3, Martin Goros4, Joel Michalek4, Kevin Kelly5, Steve Weitman6, Anand Karnad2. 1. Department of Medicine, Division of Hematology and Oncology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, Mail Code 8221, San Antonio, TX 78229-3900, USA. Electronic address: jhr789@gmail.com. 2. Department of Medicine, Division of Hematology and Oncology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, Mail Code 8221, San Antonio, TX 78229-3900, USA. 3. Department of Medicine, Division of Internal Medicine, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, Mail Code 8221, San Antonio, TX 78229-3900, USA. 4. Department of Epidemiology and Biostatistics, University of Texas Health Science Center at San Antonio, TX, USA. 5. Department of Medicine, Division of Hematology and Oncology, Cancer Therapy and Research Center, 7979 Wurzbach Road, Mail Code 8232, San Antonio, TX 78229-3900, USA. 6. Institute for Drug Development, Cancer Therapy and Research Center, 7979 Wurzbach Road, Mail Code 8232, San Antonio, TX 78229-3900, USA.
Abstract
OBJECTIVE: Elderly patients with cancer are under-represented in clinical trials, and there is especially scant data on their participation in early-phase trials. In an effort to provide more data, we reviewed our Phase I experience. METHODS: We conducted a retrospective analysis of 461 patients enrolled in Phase I clinical trials at the Cancer Therapy Research Center (CTRC) from 2009 to 2011 to determine the rate of completion of at least 12 weeks of treatment, incidence of adverse events, prevalence of co-morbidities, functional status, and survival. Elderly (E) was defined as ≥70 years; non-elderly (NE) was defined as ≤69 years. RESULTS: The elderly represented 15% (69/461) of enrolled patients. The most common malignancies were colon (20%), hematologic (18%), lung (15%), and breast (8%). The median age of E was 72 years (range 70-85, SD 3.15), and 49% of the E was female. Co-morbidities (E vs. NE) include diabetes (28% vs. 23%), hypertension (65% vs. 44%), and chronic kidney disease (91% vs. 48%). Thirty-two percent of E vs. 37% of NE completed at least 12 weeks of treatment. Reasons for not completing in E vs. NE respectively were progression of disease (43% vs. 61%), toxicity (28% vs. 9%), and self-withdrawal (11% vs. 7%). Reasons for not completing the protocol was significantly associated with being elderly (p = 0.005). There were non-significant differences in toxicity in E vs. NE CONCLUSION: Elderly patients have a higher likelihood of not completing trials for reasons including toxicity. This highlights the need for better Phase I trial-designs incorporating ideal geriatric assessment tools.
OBJECTIVE: Elderly patients with cancer are under-represented in clinical trials, and there is especially scant data on their participation in early-phase trials. In an effort to provide more data, we reviewed our Phase I experience. METHODS: We conducted a retrospective analysis of 461 patients enrolled in Phase I clinical trials at the Cancer Therapy Research Center (CTRC) from 2009 to 2011 to determine the rate of completion of at least 12 weeks of treatment, incidence of adverse events, prevalence of co-morbidities, functional status, and survival. Elderly (E) was defined as ≥70 years; non-elderly (NE) was defined as ≤69 years. RESULTS: The elderly represented 15% (69/461) of enrolled patients. The most common malignancies were colon (20%), hematologic (18%), lung (15%), and breast (8%). The median age of E was 72 years (range 70-85, SD 3.15), and 49% of the E was female. Co-morbidities (E vs. NE) include diabetes (28% vs. 23%), hypertension (65% vs. 44%), and chronic kidney disease (91% vs. 48%). Thirty-two percent of E vs. 37% of NE completed at least 12 weeks of treatment. Reasons for not completing in E vs. NE respectively were progression of disease (43% vs. 61%), toxicity (28% vs. 9%), and self-withdrawal (11% vs. 7%). Reasons for not completing the protocol was significantly associated with being elderly (p = 0.005). There were non-significant differences in toxicity in E vs. NE CONCLUSION: Elderly patients have a higher likelihood of not completing trials for reasons including toxicity. This highlights the need for better Phase I trial-designs incorporating ideal geriatric assessment tools.
Authors: Joy H Lewis; Meredith L Kilgore; Dana P Goldman; Edward L Trimble; Richard Kaplan; Michael J Montello; Michael G Housman; José J Escarce Journal: J Clin Oncol Date: 2003-04-01 Impact factor: 44.544
Authors: G Folprecht; D Cunningham; P Ross; B Glimelius; F Di Costanzo; J Wils; W Scheithauer; P Rougier; E Aranda; H Hecker; C-H Köhne Journal: Ann Oncol Date: 2004-09 Impact factor: 32.976
Authors: Benjamin D Smith; Grace L Smith; Arti Hurria; Gabriel N Hortobagyi; Thomas A Buchholz Journal: J Clin Oncol Date: 2009-04-29 Impact factor: 44.544
Authors: M Trumper; P J Ross; D Cunningham; A R Norman; R Hawkins; M Seymour; P Harper; T Iveson; M Nicolson; T Hickish Journal: Eur J Cancer Date: 2006-02-08 Impact factor: 9.162
Authors: Giandomenico Roviello; Laura Zanotti; Maria Rosa Cappelletti; Angela Gobbi; Martina Dester; Giovanni Paganini; Chiara Pacifico; Daniele Generali; Raheleh Roudi Journal: Clin Exp Med Date: 2017-04-08 Impact factor: 3.984
Authors: C Baldini; E Charton; E Schultz; L Auroy; A Italiano; M Robert; E Coquan; N Isambert; P Moreau; S Le Gouill; C Le Tourneau; Z Ghrieb; J J Kiladjian; J P Delord; C Gomez Roca; N Vey; F Barlesi; T Lesimple; N Penel; J C Soria; C Massard; S Besle Journal: ESMO Open Date: 2022-05-06
Authors: K H Khan; T A Yap; A Ring; L R Molife; S Bodla; K Thomas; A Zivi; A Smith; I Judson; U Banerji; J S de Bono; S B Kaye Journal: Br J Cancer Date: 2016-01-12 Impact factor: 7.640
Authors: Arthur E Frankel; Keith T Flaherty; George J Weiner; Robert Chen; Nilofer S Azad; Michael J Pishvaian; John A Thompson; Matthew H Taylor; Daruka Mahadevan; A Craig Lockhart; Ulka N Vaishampayan; Jordan D Berlin; David C Smith; John Sarantopoulos; Matthew Riese; Mansoor N Saleh; Chul Ahn; Eugene P Frenkel Journal: Oncologist Date: 2017-03-17